Vanguard Group Inc Arcellx, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
 - Q2 2025
 
A detailed history of Vanguard Group Inc transactions in Arcellx, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,944,885 shares of ACLX stock, worth $356 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,944,885
              Previous 3,985,156
              
        
           1.01%
        
      
          
        Holding current value
$356 Million
            Previous $261 Million
            
        
           0.63%
        
      
          
        % of portfolio
0.0%
            Previous 0.0%
          
        Shares
	  14 transactions
	
  Others Institutions Holding ACLX
# of Institutions
223Shares Held
49.1MCall Options Held
245KPut Options Held
885K- 
    
      Paradigm Biocapital Advisors LP New York, NY4.65MShares$420 Million14.29% of portfolio
 - 
    
      Nea Management Company, LLC Timonium, MD3.75MShares$338 Million20.45% of portfolio
 - 
    
      Black Rock Inc. New York, NY3.52MShares$317 Million0.0% of portfolio
 - 
    
      Ra Capital Management, L.P. Boston, MA3.04MShares$274 Million4.37% of portfolio
 - 
    
      Vestal Point Capital, LP New York, NY2.75MShares$248 Million9.53% of portfolio
 
About Arcellx, Inc.
- Ticker ACLX
 - Exchange NASDAQ
 - Sector Healthcare
 - Industry Biotechnology
 - Shares Outstandng 43,819,200
 - Market Cap $3.95B
 - Description
 - Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...